The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action. By way of societal benefits, biosimilars have been widely expected to improve patient access to life-saving biologics while reflecting in substantial cost savings. A RAND report estimates US cost savings of over $50 billion in 10 years. However, there is wide variability in the estimates as to how biosimilars may benefit various stakeholders.
It is not always clear how these are measured, whether they are meaningful from a patient perspective, and how they can be harnessed to guide access decision making. Careful consideration of the societal benefits of biosimilars from a multi-stakeholder perspective may provide valuable lessons for fully realizing their potential.